Clinical trial · Interventional
PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
A Multicenter, Randomized, Positive Parallel Controlled Clinical Trial of PVE/PVL Combined With DEB-TACE in the Treatment of Large or Large Liver Cancer in the Right Lobe of the Liver Without Hepatectomy
NCT05103007CI-TRIAL-00072386CCGLC-004unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of PVL/PVE combined with DEB-TACE in the treatment of unresectable patients with large or large tumors in the right lobe of the liver.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DEB-TACE | Procedure | — | UNRESOLVED |
| PVL/PVE+DEB-TACE | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Drug-eluting bead transarterial chemoembolization（DEB-TACE)
- description
- Percutaneous drug-eluting bead transarterial chemoembolization, followed by conventional transarterial chemoembolization（cTACE) every 2 months. A total of 3 times of chemoembolization will be performed.
- interventionNames
- Procedure: DEB-TACE
- type
- EXPERIMENTAL
- label
- PVL/PVE+DEB-TACE
- description
- PVL and PVE will be performed randomly assigned according to 1:1 according to the random number table.
- interventionNames
- Procedure: PVL/PVE+DEB-TACE
Primary outcomes (2)
- measure
- the rate of tumor resection after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically diagnosed as large or giant hepatocellular carcinoma of the right lobe of the liver; * Child-Pugh liver function grade A, * ECOG PS 0-1 * If the tumor is resected with R0, the remaining liver volume is insufficient * ICG-15R \< 30% * No serious organic diseases of heart, lung, brain and other organs; * No history of other malignant tumors; * The patient's survival time is expected to be more than 3 months. Exclusion Criteria: * Pregnant and lactating women * History of organ transplant * Tumor thrombus with portal vein trunk or left branch involved; * distant metastasis; * Patients with obvious liver cirrhosis (Plt \< 100 × 10 \^ 9 / L at admission or gastroscopy suggested esophageal and gastric varices); * Active bleeding caused by various causes; * Suffering from severe acute or chronic diseases or infectious diseases; * History of hepatectomy or TACE treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.